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The rapid emergence (from 0% before 1998 to 6.5% in 2000) of pandrug-resistant Acinetobacter bauman-
nii (PDRAB) was noted in a university hospital in Taiwan. To understand the epidemiology of these iso-
lates, we studied 203 PDRAB isolates, taken from January 1999 to April 2000: 199 from 73 hospitalized
patients treated at different clinical settings in the hospital and 4 from environmental sites in an intensive-
care unit. Pulsed-field gel electrophoresis analysis and random amplified polymorphic DNA (RAPD) gener-
ated by arbitrarily primed polymerase chain reaction of these 203 isolates showed 10 closely related gen-
otypes (10 clones). One (clone 5), belonging to pulsotype E and RAPD pattern 5, predominated (64
isolates, mostly from patients in intensive care). Increasing use of carbapenems and ciprofloxacin (selec-
tive pressure) as well as clonal dissemination might have contributed to the wide spread of PDRAB in this
hospital.
he emergence and rapid spread of multidrug-resistant iso-
lates causing nosocomial infections are of great concern
worldwide (1–5). Although methicillin-resistant Staphylococ-
cus aureus, vancomycin-resistant enterococci, and extended-
spectrum  β -lactamase and AmpC–producing Enterobacteri-
aceae have been the subject of much of this attention, multi-
drug resistance among some non-Enterobacteriaceae
organisms, such as Acinetobacter baumannii, has also
emerged (1–10).
During the last decade, nosocomial infections caused by
multidrug-resistant  A. baumannii have been reported
(3,4,6,7,11–13). Initial concern about carbapenem-resistant A.
baumannii (CRAB) began when the first nosocomial outbreak
occurred in the United States in 1991 (6). Since then, CRAB
infections and hospitalwide outbreaks have been reported from
many other countries (7,11,14–17). 
In May 1998, the first isolate of CRAB—which was also
resistant to almost all commercially available antibiotics,
including all cephalosporins, aztreonam, aminoglycosides, and
ciprofloxacin (pandrug-resistant A. baumannii, PDRAB)—
was recovered from a leukemia patient with bacteremia in an
oncology ward. Three more isolates of PDRAB were recov-
ered from three patients admitted to three general wards in
January–February 1999. Since April 1999, clusters of PDRAB
isolates were found in patients infected or colonized by these
organisms throughout the hospital, particularly in patients hos-
pitalized in several intensive-care units (ICUs). The outbreak
persisted for more than 12 months, beginning April 1999, and
involved 73 patients. The aim of our study was to document
the emergence of PDRAB in a university hospital and to char-
acterize a hospitalwide outbreak due to PDRAB by investigat-
ing antibiotypes and genotypes by pulsed-field gel
electrophoresis (PFGE) and arbitrarily primed polymerase
chain reaction (APPCR).
Materials and Methods
Background
National Taiwan University Hospital (NTUH) is a 2,000-
bed hospital located in northern Taiwan. The Nosocomial
Infection Control Committee of the hospital was established in
1980. Since then, identification of pathogens that cause noso-
comial infections and collection and analysis of antimicrobial
susceptibility results of these pathogens from the hospital’s
clinical microbiology laboratory have been performed (4).
Definitions for nosocomial infection followed the guidelines
of the National Nosocomial Infections Surveillance system
(4,18). 
To determine the secular trend of CRAB, we analyzed data
on the disk-diffusion susceptibilities to imipenem of this
organism recovered in the period 1993–2000 in NTUH.
Organisms were categorized as susceptible, intermediate, or
resistant to the antimicrobial agents tested on the basis of
guidelines provided by the National Committee for Clinical
Laboratory Standards (NCCLS) (19). PDRAB described iso-
lates resistant to almost all commercially available antibiotics
tested (i.e., ceftazidime, cefepime, ticarcillin-clavulanate, pip-
eracillin-tazobactam, aztreonam, imipenem, meropenem, gen-
tamicin, amikacin, ofloxacin, and ciprofloxacin). Isolates of
CRAB, which did not belong to PDRAB, were usually suscep-
tible to ciprofloxacin, ofloxacin, gentamicin, or amikacin. 
The annual use of carbapenems (imipenem and mero-
penem), extended-spectrum cephalosporins (cefotaxime,
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ceftriaxone, ceftazidime, cefepime), aminoglycosides (gen-
tamicin, tobramycin, netilmicin, and amikacin), and ciproflox-
acin, expressed as grams per 1,000 patient-days from 1993 to
2000, was also analyzed. Imipenem was introduced in the hos-
pital in 1990, and cefepime and meropenem have been avail-
able since 1997 and 1998, respectively.
Bacterial Isolates
We collected 199 consecutive isolates of PDRAB recov-
ered from 72 patients colonized or infected by these organisms
from January 1999 to April 2000 and from one patient with
bacteremia in May in 1998. Multiple isolates from a single
patient were included only if they were recovered from differ-
ent body sites or recovered from the same body site more than
7 days apart. These isolates were recovered from sputum (142
isolates), wound pus (20 isolates), blood (18 isolates), bron-
chial washing (6 isolates), central venous catheter tips (5 iso-
lates), pleural fluid (3 isolates), and urine (5 isolates). Thirty-
three of these patients had more than one isolate (range 2 to 13
isolates) collected for this study. Four environmental isolates
were recovered from a ventilator monitor board (two isolates)
and tips of feeding syringe (two isolates) from an ICU. The
isolates were stored at –70°C in trypticase soy broth (Difco
Laboratories, Detroit, MI) supplemented with 15% glycerol
before being tested. 
Antimicrobial Susceptibility Testing
MICs of antimicrobial agents for the isolates were deter-
mined by means of the agar dilution method, according to
guidelines established by NCCLS (19). The following antimi-
crobial agents were provided by their manufacturers for use in
this study: ceftazidime (GlaxoSmithKline, Greenford, UK),
cefepime and amikacin (Bristol-Myers Squibb Company, Prin-
ceton, NJ), flomoxef (Shionogi & Co., Ltd. Osaka, Japan),
imipenem (Merck & Co., Inc., Rahway, NJ), meropenem
(Sumitomo Pharmaceuticals Co., Ltd., Osaka, Japan), ampicil-
lin-sulbactam and trovafloxacin (Pfizer Inc., New York, NY),
and ciprofloxacin and moxifloxacin (Bayer Corporation, West
Haven, CN). The isolates were grown overnight on trypticase
soy agar plates supplemented with 5% sheep blood (BBL
Microbiology Systems, Cockeysville, MD) at 37°C. Bacterial
inocula were prepared by suspending the freshly grown bacte-
ria in sterile normal saline and adjusted to a 0.5 McFarland
standard. With the use of a Steers replicator, an organism den-
sity of 104 CFU/spot was spread onto the unsupplemented
Mueller-Hinton agar (BBL Microbiology Systems) with vari-
ous concentrations of antimicrobial agents and incubated at
35°C in ambient air. 
Time-Kill Determination
Two PDRAB isolates were tested according to methods
described previously (20–22). Antibiotic combinations tested
included imipenem plus amikacin, imipenem plus ciprofloxa-
cin, imipenem plus ampicillin-sulbactam, and ciprofloxacin
plus ampicillin-sulbactam. In each case, concentration of MIC
and one to eight twofold dilutions lower than the MICs were
tested. Viability counts were performed at 0, 2, 4, 8, and 24
hours. Synergy was defined as a decrease of >2 µg/mL in via-
bility count of the combination at 24 h compared to that with
the more active of the two agents used alone (22). 
Molecular Typing
Genotyping was determined by the random amplified poly-
morphic DNA (RAPD) patterns generated by APPCR and by
the pulsotypes generated by PFGE. APPCR was performed
with two random oligonucleotide primers: OPA-05 and OPA-
02 (Operon Technologies, Inc., Alameda, CA) under conditions
described previously (8). For PFGE, DNA extraction and puri-
fication were also carried out as described previously (11).
DNA was digested by the restriction enzyme SmaI, and the
restriction fragments were separated in a CHEF-DRIII unit
(Bio-Rad Laboratories, Hercules, CA) at 200 V for 27 h. Inter-
pretation of the PFGE profiles followed the description by Ten-
over et al. (23). PFGE profiles of the isolates were considered
derived from a common ancestor (closely related isolates), if
the numbers of fragment differences were three or less (23).
Results
Trend of CRAB and PDRAB
The rapidly increasing incidence of CRAB (from 5.88% in
1993 to 21.5% in 2000) and PDRAB (0% before 1998 to 6.5%
in 2000) as causes of nosocomial infection is shown in Figure
1. This trend correlates with the increasing use of carbapenem
and ciprofloxacin but not with the use of extended-spectrum
cephalosporins and aminoglycosides. 
Antimicrobial Susceptibilities
All PDRAB isolates were also nonsusceptible to all of the
antibiotics tested by the agar dilution method (Table 1). Most
Figure 1. Annual consumption (gram/patient-day x 1,000) of carbapen-
ems (imipenem and meropenem), extended-spectrum cephalosporins
(cefotaxime, ceftroaxone, ceftazidime, and cefepime), ciprofloxacin,
aminoglycosides (gentamicin, tobramycin, netilmicin, and amikacin)
and percent of isolates of imipenem-resistant and pandrug-resistant
Acinetobacter baumannii (PDRAB) at the National Taiwan University
Hospital, 1993–2000.Emerging Infectious Diseases  •  Vol. 8, No. 8, August 2002 829
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(62%) of the isolates were intermediate to imipenem, although
only 8% of these isolates were intermediate to meropenem.
Only 3% of these isolates were susceptible to ampicillin-sul-
bactam. The MIC90 of trovafloxacin and moxifloxacin was 16
µg/mL for each.
Synergy Tests
The results of the time-kill study of the two isolates
tested—one (isolate I) that belonged to clone 5 and the other
(isolate II) that belonged to clone 6 (see below)—are shown
(Table 2). Only imipenem plus amikacin and imipenem plus
ampicillin-sulbactam showed synergy against isolate I; syn-
ergy was detected for all four combinations for isolate II. The
MICs of the two combinations with synergistic activity for iso-
late I remained in the resistant ranges. On the other hand, the
MICs of two (imipenem plus amikacin and imipenem plus
ciprofloxacin) of the four combinations for isolate II were
within the susceptible ranges.
PFGE and APPCR Analysis
A total of 10 PFGE profiles, pulsotypes A to J, were identi-
fied among the isolates recovered from 73 patients (Figure
2A). Pulsotype E isolates were further separated into 10 sub-
types, subtypes E1 to E10 (Figure 2B). Most (46.9%) of the
subtypes among the strain isolates of pulsotype E were sub-
type E2, followed by E3 (17.2%) and E6 (12.5%). For RAPD
Table 1. In vitro susceptibilities for 203 clinical isolates of pandrug-resis-
tant Acinetobacter baumannii (PDRAB) determined by disk diffusion
MIC (µg/mL) % of isolates
Antibiotic Range MIC50 MIC90 SI R
Ampicillin 64–>128 >128 >128 - - -
SAM 4–>128 64 128 3 3 94
Ceftazidime 16–>128 >128 >128 0 1 99
Cefepime 16–>128 >128 >128 0 1 99
Flomoxef 64–>128 >128 >128 - - -
TZP 32–>128 >128 >128 0 4 96
Aztreonam 8–>128 64 128 1 1 98
Imipenem 8–64 8 32 0 62 38
Meropenem 8–128 16 128 0 8 92
Amikacin 32–>128 >128 >128 0 6 94
Ciprofloxacin 2–>128 64 128 0 6 94
Trovafloxacin 4–32 8 16 - - -
Moxifloxacin 2–16 8 16 - - -
TZP, piperacillin-tazobactam; SAM, ampicillin-sulbactam.
Table 2. Results of time-kill study of two isolates of pandrug-resistant 
Acinetobacter baumannii (PDRAB)
MIC (µg/mL)a
Isolate I Isolate II
Antibiotic (clone 5) (clone 6)
Alone
Imipenem 32 32
Amikacin 128 64
Ciprofloxacin 128 2
Ampicillin-sulbactam 128 32
Combination
Imipenem + amikacin 16/64 2/4
Imipenem + ciprofloxacin 32/128 4/0.25
Imipenem + ampicillin-sulbactam 16/64 8/8
Ciprofloxacin + ampicillin-sulbactam 128/128 1/16
aValues are the lowest concentrations (µg/mL) of each agent in combination that yielded 
synergy.
Figure 2. (A) Ten pulsotypes obtained by pulsed-field gel electrophore-
sis (PFGE) after digestion with SmaI. Lane M, molecular size marker.
Lanes A to J, pandrug-resistant Acinetobacter baumannii (PDRAB) iso-
lates belonging to pulsotypes A to J, respectively. (B) Ten subtypes of
pulsotype E. Lanes M, molecular size marker. Lane E1 to E10, PDRAB
isolates belonging to subtypes E1 to E10, respectively.RESEARCH
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analysis using the two primers (OPA-02 and OPA-05), 10
RAPD patterns, patterns 1 to 10, were recognized (Figure 3, A
and B). The 10 patterns correlated well with the 10 pulsotypes.
Isolates recovered from various body sites of the same patient
had identical pulsotypes and RAPD patterns.
Among the isolates, one clone (clone 5) belonging to pul-
sotype E and RAPD pattern 5 predominated (64 isolates) and
most isolates (43, 67.2%) of this strain were recovered from
ICU patients, particularly from November 1999 to April 2000
(Figure 4, A and B). The first PDRAB isolate in 1998
belonged to pulsotype A. The first clone 5 isolate was subtype
E1, identified in April in an ICU (ICU-2); subtype E2 was
found in another unit (ICU-7) in May. All four isolates from
the equipment in ICU-4 in February 2000 belonged to clone 5
(subtype E2). 
Discussion
This report describes the trends of nosocomial infections
caused by PDRAB in a university hospital and characterizes a
hospitalwide epidemic due to these organisms during a 16-
month period. Our results suggest three important facets. First,
the upward trend in CRAB in the past 8 years and rapid emer-
gence of PDRAB in the last 3 years are impressive. This phe-
nomenon correlated with the level of annual use of
ciprofloxacin and carbapenems in the hospital. However, risk
factors for acquiring PDRAB should be studied before attrib-
uting the emergence of PDRAB clones to carbapenem and
other antibiotic consumption, and before implementing an
antibiotic- (particularly carbapenem) restriction program as an
infection-control measure to eradicate the outbreak. Second,
by using PFGE and APPCR, we demonstrated the spread of
one epidemic clone in 64 of 73 patients, and nine other geno-
types were observed in the outbreak PDRAB isolates. Wide-
spread dissemination of the major clone (clone 5) in all ICUs
and in most general wards of the hospital contributed to the
rapid emergence of PDRAB in the hospital. Third, contrary to
the findings by other investigators (20,21,24), imipenem plus
amikacin, ciprofloxacin, and ampicillin-sulbactam, in the com-
binations tested, exhibited weak activity against the major
clone (clone 5) of PDRAB. Newer fluorquinolones (trovaflox-
acin and moxifloxacin) also had limited potency against these
PDRAB isolates. 
 Isolates of A. baumannii, particularly those recovered
from patients with nosocomial infections, are frequently resis-
tant to multiple antimicrobial agents, including cephalospor-
ins, aminoglycosides, and quinolones (3,4,12,24). Imipenem is
the most effective agent against this organism. However, with
the increasing use of carbapenems and other antibiotics (such
as ciprofloxacin and amikacin), particularly in institutions that
have an increasing incidence of extended-spectrum β -lacta-
mase–producing Enterobacteiraceae or those with hyperpro-
duction of AmpC enzymes, the rapid and progressive
emergence of CRAB and PRRAB is unavoidable (3,4,6,7,11).
This phenomenon was illustrated in many countries as well as
in numerous major teaching hospitals in Taiwan, including
NTUH (3,4). 
Different mechanisms have been involved in A. baumannii
isolates resistant to cephalosporins and carbapenems: the
altered penicillin-binding proteins, the presence of various
types of β -lactamases, and the loss of porins (8,17,25). Investi-
gation of these resistance mechanisms in our PDRAB isolates
is ongoing. Although resistance emerged after considerable
pressure from carbapenem use in our hospital, molecular typ-
ing approaches demonstrated that the rapid emergence of
PDRAB was less likely caused by the acquisition of different
resistant mechanisms by preexisting multiple clones than by
the introduction of a new clone (clone 5). After detection of
the first clone 5 isolate, this strain was found in many infected
or colonized ICU patients as well as in patients admitted in the
general wards—despite the implementation of isolation pre-
caution and environmental surveillance. At the end of this
study, the epidemic is still occurring. Further control measures
such as restriction of carbapenem use (particularly in ICUs),
intensification and modification of cleaning procedures for
contaminated equipment, and cohorting the patients infected
or colonized with CRAB or PDRAB are now being under-
taken.
Previous studies of gram-negative bacilli, such as combi-
nations of a β -lactam with amikacin, which were synergistic in
vitro, have been associated with better outcomes than those
achieved with nonsynergistic regimens, particularly in debili-
tated patients with severe infections (26). In recent reports on
Figure 3. Random amplified polymorphic DNA (RAPD) patterns gener-
ated by arbitrarily primed polymerase chain reaction for pandrug-resis-
tant  Acinetobacter baumannii (PDRAB) isolates using two primers
OPA-05 (A) and OPA-02 (B). Lane M, molecular size marker. Lanes A
to J, RAPD patterns 1 to 10. Isolates of PDRAB belonging to pulso-
types A to J exhibit RAPD pattern 1–10, respectively.Emerging Infectious Diseases  •  Vol. 8, No. 8, August 2002 831
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multidrug-resistant A. baumannii isolates, combinations of
imipenem plus amikacin or tobramycin had better bactericidal
activity against these isolates than imipenem plus sulbactam
(21). Moreover, for isolates with a high MIC of amikacin (>32
µg/mL) and ciprofloxacin (>4 µg/mL), amikacin, or ciproflox-
acin MICs in combination with in vitro synergy were not
achievable clinically (20). Our study partly supports these
findings. Although synergy was detected for combinations of
imipenem plus amikacin and imipenem plus ampicillin-sul-
bactam, MICs of these agents exceeded the levels achievable
in plasma, suggesting their limited potential as treatment regi-
mens. Some of our patients with bacteremia due to clone 5 A.
baumannii could be treated successfully with a higher dose of
imipenem (3 g/day) plus amikacin. However, this regimen
could not eradicate the organisms from respiratory secretions
and wound pus (data not shown). Further in vitro and in vivo
studies should be conducted to establish the treatment guide-
lines for CRAB or PDRAB infections.
In summary, we report a nosocomial outbreak due to a
major clone of PDRAB in a hospital with widespread carbap-
enem use. This new emerging PDRAB can be considered a
harbinger of the so-called post-antibiotic era. To confront the
imminent threat of untreatable infection caused by this organ-
ism, a correct antibiotic strategy should be addressed, and
strict compliance with basic and potential control measures for
the containment of infection should be instituted.
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